Downregulation of DBN1 is related to vincristine resistance in colon cancer cells

被引:7
作者
Han, Zhongmin [1 ]
Huang, Hemei [1 ]
Zhang, Tao [1 ]
机构
[1] Zhengzhou Railway Vocat & Tech Coll, Dept Med Technol, Zhengzhou 450052, Henan, Peoples R China
关键词
Colon cancer; DBN1; drug resistance; HCT-8; vincristine; DRUG-RESISTANCE; P-GLYCOPROTEIN; EXPRESSION; MECHANISM;
D O I
10.4103/0973-1482.192766
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: This study was aimed to investigate the relationship between the expression of drebrin (DBN1) gene and resistance in colon cancer to reveal the mechanism of tumor drug resistance and provide a basis for the reversal of this drug resistance in tumor cells. Materials and Methods: The human colon carcinoma cell line HCT-8 was used, and vincristine (VCR)-resistant colon cancer cell line HCT-8/V was established by gradually increasing the concentration of VCR. Polymerase chain reaction (PCR) primers were designed for DBN1 gene. The DBN1 differential expression in colon cancer sensitive and resistant cell lines was detected by fluorescence quantitative PCR. Western blot analysis was used to study DBN1 expression in the resistant cells further. Results: VCR resistance of HCT-8/V cell line was established. Quantitative PCR and Western blot results showed that DBN1 expression in the resistant cell line was significantly lower, the difference being statistically significant (P < 0.05). Conclusion: Low DBN1 gene expression may be associated with colon cancer cell resistance to VCR.
引用
收藏
页码:38 / 41
页数:4
相关论文
共 24 条
[1]   Expression of Dbn1 during mouse brain development and neural stem cell differentiation [J].
Ao, Xiang ;
Liu, Yunlai ;
Qin, Maolin ;
Li, Chengren ;
Chen, Xingshu ;
Xiao, Lan ;
Liu, Jianjun .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2014, 449 (01) :81-87
[2]   Inhibition of IGF1-R overcomes IGFBP7-induced chemotherapy resistance in T-ALL [J].
Bartram, Isabelle ;
Erben, Ulrike ;
Ortiz-Tanchez, Jutta ;
Blunert, Katja ;
Schlee, Cornelia ;
Neumann, Martin ;
Heesch, Sandra ;
Baldus, Claudia D. .
BMC CANCER, 2015, 15
[3]   A combination treatment with DNA methyltransferase inhibitors and suramin decreases invasiveness of breast cancer cells [J].
Borges, Sahra ;
Doeppler, Heike R. ;
Storz, Peter .
BREAST CANCER RESEARCH AND TREATMENT, 2014, 144 (01) :79-91
[4]   A CRITICAL-REVIEW OF THE USE OF VINCRISTINE (VCR) AS A TUMOR-CELL SYNCHRONIZING AGENT IN CANCER-THERAPY [J].
CAMPLEJOHN, RS .
CELL AND TISSUE KINETICS, 1980, 13 (03) :327-335
[5]   P-glycoprotein and cytochrome P450 3A4 involvement in risperidone transport using an in vitro Caco-2/TC7 model and an in vivo model [J].
Cousein, Etienne ;
Barthelemy, Christine ;
Poullain, Stephanie ;
Simon, Nicolas ;
Lestavel, Sophie ;
Williame, Virginie ;
Joiris, Etienne ;
Danel, Cecile ;
Clavey, Veronique ;
Brossard, Denis ;
Robert, Hugues ;
Crauste-Manciet, Sylvie ;
Vaccher, Claude ;
Odou, Pascal .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2007, 31 (04) :878-886
[6]  
Dong WH, 2015, INT J CLIN EXP PATHO, V8, P11524
[7]   Simple, Time-Saving Dye Staining of Proteins for Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis Using Coomassie Blue [J].
Dong, Wei-Hua ;
Wang, Tian-Yun ;
Wang, Fang ;
Zhang, Jun-He .
PLOS ONE, 2011, 6 (08)
[8]  
Dumontet Charles, 2004, Bull Cancer, V91, pE81
[9]   Selection of resistant acute myeloid leukemia SKM-1 and MOLM-13 cells by vincristine-, mitoxantrone- and lenalidomide-induced upregulation of P-glycoprotein activity and downregulation of CD33 cell surface exposure [J].
Imrichova, D. ;
Messingerova, L. ;
Seres, M. ;
Kavcova, H. ;
Pavlikova, L. ;
Coculova, M. ;
Breier, A. ;
Sulova, Z. .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 77 :29-39
[10]   Analysis of ERBB Ligand-Induced Resistance Mechanism to Crizotinib by Primary Culture of Lung Adenocarcinoma with EML4-ALK Fusion Gene [J].
Kimura, Madoka ;
Endo, Hiroko ;
Inoue, Takako ;
Nishino, Kazumi ;
Uchida, Junji ;
Kumagai, Toru ;
Kukita, Yoji ;
Kato, Kikuya ;
Imamura, Fumio ;
Inoue, Masahiro .
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (03) :527-530